Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma

Roberti, Elisabetta; Merlano, Marco; Ravanelli, Marco; Alberti, Andrea; Esposito, Andrea; Gili, Riccardo; Spinazzé, Silvia; Baré, Cristina; Jocollè, Genny; Benasso, Marco; Bertolotti, Francesca; Vecchio, Stefania; Bacigalupo, Almalina; Licitra, Lisa; Denaro, Nerina; D’Amico, Mauro; Lorini, Luigi; Gurizzan, Cristina; Alfieri, Salvatore; Bossi, Paolo

doi:10.1016/j.oraloncology.2023.106540

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our report shows that a high percentage of breast cancer patients have a deteriorated QMI when adjusted for BMI, ASMMI, and FMI. This condition is even more evident in overweight and obese women, and although we did not find sarcopenia or cancer cachexia, the results indicate a need to monitor muscle quality in breast cancer patients to improve outcomes [37]. The authors concluded that intermuscular adipose tissue may be responsible for shorter progression-free survival, leading to changes in muscle quality without affecting the muscle quantity and worsening the patient's prognosis [13].…”

Section: Discussionmentioning

confidence: 72%

Role of Incretins in Muscle Functionality, Metabolism, and Body Composition in Breast Cancer: A Metabolic Approach to Understanding This Pathology

Martínez-Herrera,

Muñoz-García,

José-Ochoa

et al. 2024

Biomedicines

View full text Add to dashboard Cite

A poorly studied issue in women with breast cancer is the role of incretins (GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1)) in the quantity and quality of muscle mass in lean and obese individuals. The current report aims to analyze the patterns of association and the role of incretin in muscle functionality and body composition in women with cancer compared with healthy women (mammography BI-RADS I or II) to elucidate whether GIP and GLP-1 can be used to estimate the risk, in conjunction with overweight or obesity, for breast cancer. We designed a case–control study in women with a breast cancer diagnosis confirmed by biopsy in different clinical stages (CS; n = 87) and healthy women with a mastography BI-RADS I or II within the last year (n = 69). The women were grouped according to body mass index (BMI): lean (<25 kg/m2BS), overweight (≥25–<30 kg/m2BS), and obese (≥30 kg/m2BS). We found that GLP-1 and GIP levels over 18 pg/mL were associated with a risk of breast cancer (GIP OR = 36.5 and GLP-1 OR = 4.16, for the entire sample), particularly in obese women (GIP OR = 8.8 and GLP-1 OR = 6.5), and coincidentally with low muscle quality indexes, showed an association between obesity, cancer, incretin defects, and loss of muscle functionality.

show abstract

Section: Discussionmentioning

confidence: 72%

Role of Incretins in Muscle Functionality, Metabolism, and Body Composition in Breast Cancer: A Metabolic Approach to Understanding This Pathology

Martínez-Herrera,

Muñoz-García,

José-Ochoa

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Furthermore, this alteration in functionality could be more related to the alteration of muscle quality than to the quantity. Roberti et al [ 30 ] found that the amount of intermuscular fat deposits induces alterations of muscle quality without alterations of muscle quantity influencing the patient prognosis. Pereira et al [ 31 ] did not identify a correlation between sarcopenia and the rate of adverse surgical outcomes in patients with early-stage breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Influence of the Results of Control of Intakes, Proteins and Anthropometry Nutritional Screening, Sarcopenia and Body Composition on the Clinical Evolution of Hospitalized Patients

Márquez Mesa,

Suárez Llanos,

Afonso Martín

et al. 2023

Nutrients

View full text Add to dashboard Cite

(1) Background: Hospital malnutrition and sarcopenia are common in inpatients and are associated with worse prognosis. Our objective is to determine the association of the positivity of CIPA (Control of Intakes, Proteins and Anthropometry) nutrition screening tool and sarcopenia and evaluate its prognostic implications (length of stay, readmissions and mortality) as well as different components of body composition. (2) Methodology: Cross-sectional single-center study and prospective six months follow-up for prognostic variables. On admission, CIPA and EWGSOP2 criteria were assessed. (3) Results: Four hundred inpatients, a median of 65.71 years old and 83.6% with high comorbidity, were evaluated. In total, 34.8% had positive CIPA and 19.3% sarcopenia. Positive CIPA and sarcopenia had worse results in body composition (fat mass (FM), fat-free mass (FFM) and appendicular skeletal muscle mass index (ASMI)) and dynamometry. Positive CIPA is significantly associated with worse prognosis (mortality (OR = 1.99), readmissions (OR = 1.86) and length of stay (B = 0.19)). Positive CIPA and sarcopenia combined are associated with a tendency to higher mortality (OR = 2.1, p = 0.088). Low hand grip strength (HGS) is significantly related to a higher length of stay (B = −0.12). (4) Conclusions: In hospitalized patients, malnutrition independently and combined with sarcopenia is associated with a worse prognosis but not body composition. Low HGS is related to a higher length of stay.

show abstract

Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia

Diallo,

Blessing,

Ihorst

et al. 2024

Skeletal Radiol

View full text Add to dashboard Cite

Objective Fatty infiltration of skeletal muscle (Myosteatosis) is associated with increased frailty, decreased muscle and mobility function, which seems fairly prevalent in multiple myeloma (MM) patients. This study aimed to determine the prognostic value of myosteatosis assessed by CT for progression-free survival (PFS) and overall survival (OS). Materials and methods This IRB-approved cohort study included patients with newly diagnosed MM who were treated at a single university hospital and received CT at baseline. Geriatric assessment was performed via International Myeloma Working Group frailty score and Revised Myeloma Comorbidity Index. Myosteatosis was determined through measurement of paravertebral muscle radiodensity. Statistical analyses included uni- and multivariable Cox proportional hazard models and the Kaplan–Meier-method. Results A total of 226 newly diagnosed MM patients (median age: 65 years [range: 29–89], 63% males, mean BMI: 25 [14–42]) were analyzed. The prevalence of myosteatosis was 51%. Muscle radiodensity was significantly decreased in individuals with International Staging System stage III vs. I (p < 0.001), indicating higher fatty muscle infiltration in patients with advanced disease. Both PFS and OS were significantly decreased in patients with myosteatosis (PFS: median 32.0 months (95% CI 20.5.5–42.2) vs. 66.4 months without myosteatosis (95% CI 42.5-not reached), p < .001); OS: median 58.6 (95% CI 51.3—90.2) vs. not reached, p < .001). Myosteatosis remained an independent predictor of OS in multivariable analyses (HR: 1.98; 95%-CI: 1.20–3.27). Conclusion Myosteatosis seems fairly prevalent in patients with newly diagnosed MM and associated with impaired overall survival. Prospective clinical trials are required to better understand the role of myosteatosis in MM patients.

show abstract

Muscle quality and not quantity as a predictor of survival in head and neck squamous cell carcinoma

Cited by 3 publications

References 35 publications

Role of Incretins in Muscle Functionality, Metabolism, and Body Composition in Breast Cancer: A Metabolic Approach to Understanding This Pathology

Role of Incretins in Muscle Functionality, Metabolism, and Body Composition in Breast Cancer: A Metabolic Approach to Understanding This Pathology

Influence of the Results of Control of Intakes, Proteins and Anthropometry Nutritional Screening, Sarcopenia and Body Composition on the Clinical Evolution of Hospitalized Patients

Myosteatosis in multiple myeloma: a key determinant of survival beyond sarcopenia

Contact Info

Product

Resources

About